The FDA on Oct. 27 released draft guidance that could speed approval of some gene-editing treatments built for a single patient's genetic mutation, a step rare disease families have pushed for since a Philadelphia infant received the first personalized CRISPR-based therapy last year.
The guidance outlines how one biologics license application, or BLA, could cover many patient-specific versions of a therapy. Under the plan, a new version that falls within preset limits could be added using laboratory data instead of a new clinical trial. The document is a draft open for public comment, and it does not approve any treatment.